High Risk MDS: Would Pre-Transplantation Chemotherapy Be Preferable?

Myelodysplastic syndromes （MDS） are clonal hematopoietic disorders characterized by ineffective hematopoiesis, marrow dysplasia and high risk of transforming into acute myelogenous leukemia （AML）. Allogeneic hematopoietic stem cell transplantation （Allo-HSCT） is currently the only method to cure MDS, especially for high-risk MDS patients. However, whether pre-transplantation chemotherapy or not is the most controversial topic among the blood academia. Regarding to this subject, we conclude that pre-transplantation chemotherapy can help the patients gain best benefits, referring to the extensive literatures and our clinical experiences.